StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS – Free Report) in a research note published on Friday morning. The firm issued a sell rating on the biotechnology company’s stock.
Other analysts also recently issued reports about the stock. Oppenheimer decreased their target price on shares of Cellectis from $11.00 to $10.00 and set an outperform rating for the company in a research report on Wednesday, June 12th. JMP Securities reiterated a market outperform rating and set a $6.00 price target on shares of Cellectis in a research note on Friday, May 31st.
Read Our Latest Analysis on CLLS
Cellectis Trading Up 0.5 %
Cellectis (NASDAQ:CLLS – Get Free Report) last posted its quarterly earnings results on Tuesday, May 28th. The biotechnology company reported ($0.15) earnings per share for the quarter. The firm had revenue of $6.50 million for the quarter. Cellectis had a negative return on equity of 67.41% and a negative net margin of 529.81%. As a group, sell-side analysts anticipate that Cellectis will post -0.54 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Cellectis stock. Baillie Gifford & Co. boosted its holdings in shares of Cellectis S.A. (NASDAQ:CLLS – Free Report) by 1.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 827,248 shares of the biotechnology company’s stock after purchasing an additional 10,605 shares during the quarter. Baillie Gifford & Co. owned about 1.49% of Cellectis worth $2,192,000 at the end of the most recent quarter. 63.90% of the stock is owned by hedge funds and other institutional investors.
About Cellectis
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.
Further Reading
- Five stocks we like better than Cellectis
- Manufacturing Stocks Investing
- Why Wall Street Analysts Raised Price Targets for Suncor Stock
- Best Aerospace Stocks Investing
- Is Super Micro Computer a Buy After Shares Sink 20% on Earnings?
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.